The COMPPARE Coordinating Center announced on September 1, 2021 that the study had reached its Pragmatic Proton enrollment goal of 900 patients, completing and closing that arm of the proton cohort. The 900th patient was enrolled by the Proton Therapy Treatment & Research Center of the Loma Linda University Medical…
The latest edition of the COMPPARE CONNECTION is now online.
Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, have been invited to participate in the seventh annual meeting of the Patient-Centered Outcomes Research Institute (PCORI), to be held virtually in November. Dr. Mendenhall and Mr. Griggs will contribute as panelists in a session focused on…
On February 17, 2021, Cancer Connections, a UF Monthly Educational & Networking Meeting, presented “COMPPARE Clinical Trial: Protons vs Photons to Treat Prostate Cancer.” Dr. Nancy Mendenhall, M.D., FACR, FASTRO, COMPPARE Principal Investigator, provided an overview of the UF-led national ongoing prostate cancer clinical trial, highlighting the differences between between…
The COMPPARE team was pleased to announce on November 13, 2020 that the study had enrolled 1,000 patients, one-third of its 3,000-patient goal. COMPPARE’s partner site, the James M. Slater, MD Proton Treatment & Research Center, Loma Linda, CA, enrolled the 1,000th patient. COMPPARE stands for “A Prospective COMparative Study…
Mr. Charles Griggs and Drs. Nancy Mendenhall and Curtiland Deville participated in “Our Health, Our Voice: Improving Prostate Cancer Outcomes through Participation in Research” on Wednesday, November 4, 2020. The live information session, presented by 100 Black Men of America, Inc., a COMPPARE partner organization, focused on the…
If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist. Approximately one…
The 2020 COMPPARE Workshop: Accrual, Monitoring, and Engagement, held in Amelia Island, FL, January 17 – 19, 2020, allowed researchers and patients to cross-pollinate their ideas and help COMPPARE succeed. One important outcome of the meeting, the decision to expand COMPPARE eligibility criteria, was derived from…
The COMPPARE Coordinating Center is very pleased to announce the activation of all 45 original targeted study sites. The UH Seidman Cancer Center was welcomed on June 1, 2020, for a total 12 new sites and principal investigators added to the team: UH Seidman Cancer Center, Cleveland,…
The COMPPARE team was pleased to announce in August that the study had enrolled 750 patients, 25% of its 3,000-patient goal. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” The study compares the quality of life,…
